مصطلحات الفهرس: drug safety, drug tolerability, dyspnea/si [Side Effect], febrile neutropenia/si [Side Effect], fever/si [Side Effect], human, infection/si [Side Effect], infestation/si [Side Effect], infusion related reaction/dt [Drug Therapy], infusion related reaction/si [Side Effect], monotherapy, nausea/si [Side Effect], neutropenia/si [Side Effect], pharmacodynamic parameters, pharmacokinetic parameters, pharmacological parameters, phase 3 clinical trial (topic), pneumonia/si [Side Effect], priority journal, pruritus/si [Side Effect], rigor/si [Side Effect], tachycardia/si [Side Effect], thrombocytopenia/si [Side Effect], tumor lysis syndrome/si [Side Effect], acalabrutinib/cb [Drug Combination], acalabrutinib/dt [Drug Therapy], bendamustine/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], clarithromycin/it [Drug Interaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/cm [Drug Comparison], fludarabine/dt [Drug Therapy], hydrocortisone/dt [Drug Therapy], ibrutinib/cb [Drug Combination], ibrutinib/cm [Drug Comparison], ibrutinib/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], posaconazole/it [Drug Interaction], ritonavir/it [Drug Interaction], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/it [Drug Interaction], venetoclax/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], allogeneic hematopoietic stem cell transplantation, anemia/si [Side Effect], article, backache/si [Side Effect], cancer chemotherapy, cancer immunotherapy, cancer recurrence, chronic lymphatic leukemia/dt [Drug Therapy], chronic lymphatic leukemia/th [Therapy], diarrhea/si [Side Effect], drug efficacy, drug metabolism, drug potentiation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27245Test
Future Oncology
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug safety, drug tolerability, dyspnea/si [Side Effect], febrile neutropenia/si [Side Effect], fever/si [Side Effect], human, infection/si [Side Effect], infestation/si [Side Effect], infusion related reaction/dt [Drug Therapy], infusion related reaction/si [Side Effect], monotherapy, nausea/si [Side Effect], neutropenia/si [Side Effect], pharmacodynamic parameters, pharmacokinetic parameters, pharmacological parameters, phase 3 clinical trial (topic), pneumonia/si [Side Effect], priority journal, pruritus/si [Side Effect], rigor/si [Side Effect], tachycardia/si [Side Effect], thrombocytopenia/si [Side Effect], tumor lysis syndrome/si [Side Effect], acalabrutinib/cb [Drug Combination], acalabrutinib/dt [Drug Therapy], bendamustine/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], clarithromycin/it [Drug Interaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/cm [Drug Comparison], fludarabine/dt [Drug Therapy], hydrocortisone/dt [Drug Therapy], ibrutinib/cb [Drug Combination], ibrutinib/cm [Drug Comparison], ibrutinib/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], posaconazole/it [Drug Interaction], ritonavir/it [Drug Interaction], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/it [Drug Interaction], venetoclax/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], allogeneic hematopoietic stem cell transplantation, anemia/si [Side Effect], article, backache/si [Side Effect], cancer chemotherapy, cancer immunotherapy, cancer recurrence, chronic lymphatic leukemia/dt [Drug Therapy], chronic lymphatic leukemia/th [Therapy], diarrhea/si [Side Effect], drug efficacy, drug metabolism, drug potentiation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27245Test
Future Oncology
LibKey Link

مصطلحات الفهرس: infusion related reaction/si [Side Effect], intention to treat analysis, leukocyte count, leukopenia/si [Side Effect], longitudinal study, lymphocytopenia/si [Side Effect], major clinical study, male, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil count, open study, overall survival, platelet count, pneumonia/si [Side Effect], priority journal, progression free survival, randomized controlled trial, sepsis/si [Side Effect], septic shock/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], treatment duration, treatment outcome, treatment response, treatment withdrawal, tumor lysis syndrome/si [Side Effect], vertigo/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/cm [Drug Comparison], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], liver enzyme/ec [Endogenous Compound], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/cm [Drug Comparison], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/dt [Drug Therapy], venetoclax/po [Oral Drug Administration], life expectancy, acute heart infarction/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], article, aspartate aminotransferase blood level, asthenia/si [Side Effect], atrial fibrillation/si [Side Effect], basal cell carcinoma/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical effectiveness, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], creatinine clearance, cytokine release syndrome/si [Side Effect], diarrhea/si [Side Effect], drug safety, drug tolerability, dyspnea/si [Side Effect], exploratory research, faintness/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, fever/si [Side Effect], follow up, geographic distribution, granulocytopenia/si [Side Effect], headache/si [Side Effect], heart failure/si [Side Effect], heart infarction/si [Side Effect], human, hyperglycemia/si [Side Effect], hypertension/si [Side Effect], hyperuricemia/si [Side Effect], hypotension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29065Test
The Lancet Oncology
Click here for full text options
LibKey Link

مصطلحات الفهرس: infusion related reaction/si [Side Effect], intention to treat analysis, leukocyte count, leukopenia/si [Side Effect], longitudinal study, lymphocytopenia/si [Side Effect], major clinical study, male, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil count, open study, overall survival, platelet count, pneumonia/si [Side Effect], priority journal, progression free survival, randomized controlled trial, sepsis/si [Side Effect], septic shock/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], treatment duration, treatment outcome, treatment response, treatment withdrawal, tumor lysis syndrome/si [Side Effect], vertigo/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/cm [Drug Comparison], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], liver enzyme/ec [Endogenous Compound], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/cm [Drug Comparison], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/dt [Drug Therapy], venetoclax/po [Oral Drug Administration], life expectancy, acute heart infarction/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], article, aspartate aminotransferase blood level, asthenia/si [Side Effect], atrial fibrillation/si [Side Effect], basal cell carcinoma/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical effectiveness, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], creatinine clearance, cytokine release syndrome/si [Side Effect], diarrhea/si [Side Effect], drug safety, drug tolerability, dyspnea/si [Side Effect], exploratory research, faintness/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, fever/si [Side Effect], follow up, geographic distribution, granulocytopenia/si [Side Effect], headache/si [Side Effect], heart failure/si [Side Effect], heart infarction/si [Side Effect], human, hyperglycemia/si [Side Effect], hypertension/si [Side Effect], hyperuricemia/si [Side Effect], hypotension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29065Test
The Lancet Oncology
LibKey Link

مصطلحات الفهرس: creatinine/ec [Endogenous Compound], aged, all cause mortality, article, cancer growth, cancer mortality, cancer survival, chronic lymphatic leukemia/dt [Drug Therapy], clinical article, creatinine clearance, drug safety, female, follow up, gene, gene deletion, gene mutation, human, infection/si [Side Effect], male, neutropenia/si [Side Effect], open study, phase 3 clinical trial, priority journal, progression free survival, rating scale, scoring system, treatment duration, chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/dt [Drug Therapy], TP53 gene, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35653Test
New England Journal of Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: cancer survival, clinical outcome, comorbidity, drug efficacy, drug tolerability, follicular lymphoma/di [Diagnosis], follicular lymphoma/dt [Drug Therapy], human, immunoregulation, infection/si [Side Effect], maintenance therapy, medical decision making, nonhodgkin lymphoma/di [Diagnosis], nonhodgkin lymphoma/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], patient monitoring, patient preference, priority journal, progression free survival, review, second cancer/si [Side Effect], survival time, symptom, T cell depletion, treatment duration, treatment response, tumor volume, bendamustine/ae [Adverse Drug Reaction], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], CD20 antibody/cb [Drug Combination], CD20 antibody/dt [Drug Therapy], obinutuzumab/dt [Drug Therapy], prednisolone/ae [Adverse Drug Reaction], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], overall survival, cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], lenalidomide/dt [Drug Therapy], advanced cancer/di [Diagnosis], age, asymptomatic disease/di [Diagnosis], Australia, cancer combination chemotherapy, cancer diagnosis, cancer immunotherapy, cancer recurrence, cancer staging, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35707Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922Test
Human Vaccines and Immunotherapeutics
Click here for full text options
LibKey Link

مصطلحات الفهرس: practice guideline, priority journal, thrombocytopenia/pc [Prevention], thrombocytopenia/si [Side Effect], time to treatment, tumor lysis syndrome/pc [Prevention], tumor lysis syndrome/si [Side Effect], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/dt [Drug Therapy], infusion related reaction/si [Side Effect], article, Australia, bleeding/pc [Prevention], bleeding/si [Side Effect], cancer chemotherapy, cancer growth, cancer recurrence, drug use, follicular lymphoma/dt [Drug Therapy], human, incidence, infection/pc [Prevention], infection/si [Side Effect], infusion related reaction/pc [Prevention], maintenance therapy, medical decision making, minimal residual disease, neutropenia/si [Side Effect], positron emission tomography, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35583Test
Asia-Pacific Journal of Clinical Oncology
LibKey Link

مصطلحات الفهرس: creatinine/ec [Endogenous Compound], aged, all cause mortality, article, cancer growth, cancer mortality, cancer survival, chronic lymphatic leukemia/dt [Drug Therapy], clinical article, creatinine clearance, drug safety, female, follow up, gene, gene deletion, gene mutation, human, infection/si [Side Effect], male, neutropenia/si [Side Effect], open study, phase 3 clinical trial, priority journal, progression free survival, rating scale, scoring system, treatment duration, chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/dt [Drug Therapy], TP53 gene, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35653Test
New England Journal of Medicine
LibKey Link

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922Test
Human Vaccines and Immunotherapeutics
LibKey Link